Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is a leader in the transplant testing market and has shown strong financial performance in recent quarters. The company has a strong management team, has successfully navigated regulatory changes, and is expanding into new markets and product offerings. With a positive outlook for the future, CareDx is poised for continued growth and potentially increased revenue and profitability.

Bears say

CareDx is heavily dependent on its AlloSure Kidney and AlloMap Heart tests for revenue, and it must generate sufficient revenue and reimbursement from these offerings to meet its expectations. However, competition and rapid changes in the diagnostic testing field could pose challenges for CDNA. Clinicians and healthcare administrators may be slow to adopt new products, potentially hindering CDNA's growth and market penetration. Furthermore, the recent draft LCD proposed lower test interval limits for kidney, heart, and lung testing, which would significantly cut CDNA's total addressable market. While the final LCD set more favorable limits, risks remain for reimbursement and pricing in the transplant and oncology markets. In addition, the company's reliance on acquisitions for growth may have an impact on its stock price.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.